Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Curtis A Lachowiez, Daniel T Peters, Jacob Fang, Andy Kaempf, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner, Joshua F Zeidner, Daniel A Pollyea, Jennifer N. Saultz

Blood (2024) 144 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2024-202118

Published: 2024

Journal Articles

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

Blood (2024) 144 (Supplement 1): 695.

https://doi.org/10.1182/blood-2024-200833

Published: 2024

Journal Articles

Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2024) 144 (Supplement 1): 2887.

https://doi.org/10.1182/blood-2024-203361

Published: 2024

Journal Articles

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Vishvaas I Ravikumar, Jessica T. Leonard, Laura F. Newell, Arpita Gandhi, Gabrielle Meyers, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jennifer N. Saultz, Jeffrey W. Tyner, Mael Heiblig, Joshua F Zeidner, Daniel A Pollyea, Curtis A Lachowiez

Blood (2024) 144 (Supplement 1): 4312.

https://doi.org/10.1182/blood-2024-201231

Published: 2024

Journal Articles

NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Jennifer N. Saultz, Manoj Rai, Andy Kaempf, Sanjog Bastola, Hyun Cho, Nicola Long, Curtis A. Lachowiez, Gabrielle Meyers, Jessica T. Leonard, Arpita Gandhi, Laura F. Newell, Brandon Hayes-Lattin, Richard T. Maziarz, Rachel J. Cook, Elie Traer, Ronan T. Swords, Jeffrey W. Tyner

Blood (2024) 144 (Supplement 1): 2859.

https://doi.org/10.1182/blood-2024-211860

Published: 2024

Journal Articles

Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia

Somya Khare, Rachel J. Cook, Amrita Desai, Arpita Gandhi, Kelli Goslee, Brandon Hayes-Lattin, Curtis A Lachowiez, Jessica T. Leonard, Richard T. Maziarz, Gabrielle Meyers, Laura F. Newell, Jennifer N. Saultz, Ronan T. Swords, Elie Traer, Eneida R Nemecek

Blood (2024) 144 (Supplement 1): 2292.

https://doi.org/10.1182/blood-2024-209407

Published: 2024

Journal Articles

Thromboprophylaxis with Intermediate Dose Low Molecular Weight Heparin in Adults Undergoing Induction with L-Asparaginase for Acute Lymphoblastic Leukemia

Hong De Sa, Thomas G Deloughery, Curtis A Lachowiez, Jessica T. Leonard, Sven R. Olson, Joseph J. Shatzel, Ronan T. Swords, Elie Traer, Brandon Hayes-Lattin

Blood (2023) 142 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2023-178918

Published: 2023

Journal Articles

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Blood (2023) 142 (Supplement 1): 1515.

https://doi.org/10.1182/blood-2023-191166

Published: 2023

Journal Articles

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Somya Khare, Staci Williamson, Brittany O'Barr, Levanto Schachter, Andy Chen, Brandon Hayes-Lattin, Jessica T. Leonard, Amrita Desai, Peter Ferreira-Gandolfo, Denise Lackey, Kevin Christmas, Richard T Maziarz, Eneida R Nemecek

Blood (2023) 142 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2023-177864

Published: 2023

Journal Articles

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

Blood (2023) 142 (Supplement 1): 978.

https://doi.org/10.1182/blood-2023-179527

Published: 2023

Journal Articles

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Jessica T. Leonard, Rachel Cook, Laura F. Newell, Arpita Gandhi, Ronan T. Swords, Christopher A. Eide, Brandon Hayes-Lattin, Kara Johnson, Elie Traer, Stephen E. Kurtz, Jennifer N. Saultz, Cristina Tognon, Jeffrey W Tyner, Curtis A. Lachowiez

Blood (2023) 142 (Supplement 1): 1512.

https://doi.org/10.1182/blood-2023-188313

Published: 2023

Journal Articles

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Blood (2023) 142 (Supplement 1): 5762.

https://doi.org/10.1182/blood-2023-188311

Published: 2023

Journal Articles

Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation

Emily C. Liang, Simone E. Dekker, Jean M.G. Sabile, Stefan Torelli, Amy Zhang, Katharine Miller, Parveen Shiraz, Brandon Hayes-Lattin, Jessica Leonard, Lori Muffly

Blood (2022) 140 (Supplement 1): 1732–1733.

https://doi.org/10.1182/blood-2022-157442

Published: 2022

Journal Articles

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Arthur Nguyen, Joseph S Bubalo, Jennifer N. Saultz, Brandon Hayes-Lattin, Andy Chen, Rachel J. Cook, Arpita Gandhi, Jessica Leonard, Richard T. Maziarz, Yazan Migdady, Eneida R. Nemecek, Levanto Schachter

Blood (2022) 140 (Supplement 1): 12856–12858.

https://doi.org/10.1182/blood-2022-156011

Published: 2022

Journal Articles

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Blood (2022) 139 (26): 3722–3731.

https://doi.org/10.1182/blood.2021014497

Published: 2022

Includes: Supplemental data

Journal Articles

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph + ALL

Jessica T. Leonard, Yoko Kosaka, Pavani Malla, Dorian LaTocha, Adam Lamble, Brandon Hayes-Lattin, Kaelan Byrd, Brian J. Druker, Jeffrey W. Tyner, Bill H. Chang, Evan Lind

Blood (2021) 137 (7): 939–944.

https://doi.org/10.1182/blood.2020005655

Published: 2021

Journal Articles

T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Jessica Leonard, MD, Yoko Kosaka, PhD, Pavani Malla, MS, Brandon Hayes-Lattin, MD, Adam J. Lamble, MD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Bill H. Chang, MD PhD, Evan F. Lind, PhD

Blood (2018) 132 (Supplement 1): 2694.

https://doi.org/10.1182/blood-2018-99-119301

Published: 2018

Journal Articles

Thromboprophylaxis with Fixed Dose, 1mg/Kg/Day, Low Molecular Weight Heparin in Adults Undergoing Induction with Asparaginase for Acute Lymphoblastic Leukemia. Results of a Single Institution Cohort Study

Luai S Al Rabadi, MD, Sven Reid Olson, MD, Joseph J. Shatzel, MD, Thomas G. Deloughery, MD MACP, FAWM, Brandon Hayes-Lattin, MD

Blood (2017) 130 (Supplement 1): 2397.

https://doi.org/10.1182/blood.V130.Suppl_1.2397.2397

Published: 2017

Journal Articles

Novel Targets Identified By in Vitro Screening of Patient Samples with Adult Acute Lymphoblastic Leukemia

Jessica T Leonard, MD, Bill H. Chang, MD PhD, Jeffrey W. Tyner, PhD, Brandon Hayes-Lattin, MD, Marc M. Loriaux, Brian J. Druker, Uma Borate, MD

Blood (2016) 128 (22): 2811.

https://doi.org/10.1182/blood.V128.22.2811.2811

Published: 2016

Journal Articles

Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax)

Jessica Leonard, MD, Joelle Rowley, Brandon Hayes-Lattin, MD, Jeffrey W. Tyner, PhD, Marc Loriaux, MD PhD, Brian J. Druker, MD, Bill H Chang, MD PhD

Blood (2015) 126 (23): 1329.

https://doi.org/10.1182/blood.V126.23.1329.1329

Published: 2015

NARROW

Immunophenotypic Markers CD7 and CD56 Improve Risk Stratification of Frontline Hypomethylating Agents + Venetoclax in Newly Diagnosed AML

Likelihood of finding an 8/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702

Purine-Analog Based Intensive Chemotherapy (IC) Combined with Venetoclax (VEN) Is Highly Active in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

PTPN11 Mutations Are Associated with Shorter Survival in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia

Impact of Social Determinants of Health on Access to Blood and Marrow Transplantation for Acute Myeloid Leukemia

Thromboprophylaxis with Intermediate Dose Low Molecular Weight Heparin in Adults Undergoing Induction with L-Asparaginase for Acute Lymphoblastic Leukemia

Results of a Phase 1 Trial Testing the Novel Combination Therapy of Venetoclax and Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Patients

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Acute Myeloid Leukemia Differentiation State and Genotype Influence Anti-Apoptotic Protein Expression, Venetoclax Sensitivity, and Survival in AML

A Phase I/II Study to Investigate the Addition of Venetoclax to Dasatinib and Steroids in Patients with Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): The Venda Trial, in Progress

Prognostic Significance of NCAM1 (CD56) Expression in AML Patients Treated with HMA+Venetoclax

Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph + ALL

T-Cell Suppression By Src/ABL Kinase Inhibitors When Combined with Blinatumomab in Ph+ Acute Lymphoblastic Leukemia

Thromboprophylaxis with Fixed Dose, 1mg/Kg/Day, Low Molecular Weight Heparin in Adults Undergoing Induction with Asparaginase for Acute Lymphoblastic Leukemia. Results of a Single Institution Cohort Study

Novel Targets Identified By in Vitro Screening of Patient Samples with Adult Acute Lymphoblastic Leukemia

Dual Targeting of Ph+ ALL with Dasatinib and ABT-199 (Venetoclax)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only